Douglas Lane & Associates LLC Has $348,000 Holdings in Becton, Dickinson and Company (NYSE:BDX)

Douglas Lane & Associates LLC decreased its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 5.4% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,534 shares of the medical instruments supplier’s stock after selling 88 shares during the quarter. Douglas Lane & Associates LLC’s holdings in Becton, Dickinson and Company were worth $348,000 as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in the business. Livelsberger Financial Advisory acquired a new position in shares of Becton, Dickinson and Company during the 3rd quarter worth about $26,000. Ashton Thomas Securities LLC acquired a new position in Becton, Dickinson and Company during the third quarter valued at approximately $33,000. Tompkins Financial Corp grew its stake in Becton, Dickinson and Company by 44.2% in the third quarter. Tompkins Financial Corp now owns 150 shares of the medical instruments supplier’s stock valued at $36,000 after purchasing an additional 46 shares in the last quarter. Sound Income Strategies LLC increased its position in shares of Becton, Dickinson and Company by 35.8% during the 3rd quarter. Sound Income Strategies LLC now owns 167 shares of the medical instruments supplier’s stock worth $40,000 after purchasing an additional 44 shares during the last quarter. Finally, Abound Wealth Management raised its stake in shares of Becton, Dickinson and Company by 96.0% during the 2nd quarter. Abound Wealth Management now owns 196 shares of the medical instruments supplier’s stock worth $46,000 after purchasing an additional 96 shares in the last quarter. Institutional investors own 86.97% of the company’s stock.

Insider Buying and Selling

In other Becton, Dickinson and Company news, EVP Roland Goette sold 638 shares of the stock in a transaction on Monday, December 9th. The stock was sold at an average price of $219.03, for a total transaction of $139,741.14. Following the transaction, the executive vice president now owns 14,217 shares in the company, valued at $3,113,949.51. This trade represents a 4.29 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Michael David Garrison sold 2,838 shares of the business’s stock in a transaction dated Thursday, December 19th. The shares were sold at an average price of $223.33, for a total transaction of $633,810.54. Following the completion of the sale, the executive vice president now directly owns 6,141 shares of the company’s stock, valued at approximately $1,371,469.53. The trade was a 31.61 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 7,959 shares of company stock valued at $1,764,340. Insiders own 0.36% of the company’s stock.

Analyst Ratings Changes

Several research firms recently weighed in on BDX. Evercore ISI raised their target price on shares of Becton, Dickinson and Company from $286.00 to $290.00 and gave the company an “outperform” rating in a research note on Tuesday, October 1st. Citigroup raised shares of Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and lifted their price objective for the company from $255.00 to $275.00 in a research report on Tuesday, October 1st. Finally, StockNews.com lowered shares of Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research note on Wednesday, December 18th. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $283.50.

Becton, Dickinson and Company Trading Up 0.8 %

Shares of Becton, Dickinson and Company stock opened at $234.04 on Thursday. Becton, Dickinson and Company has a 1 year low of $218.75 and a 1 year high of $249.89. The company has a market capitalization of $67.87 billion, a price-to-earnings ratio of 39.40, a P/E/G ratio of 1.64 and a beta of 0.39. The business has a fifty day simple moving average of $226.93 and a two-hundred day simple moving average of $232.46. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.17 and a quick ratio of 0.74.

Becton, Dickinson and Company (NYSE:BDX) last announced its earnings results on Thursday, November 7th. The medical instruments supplier reported $3.81 EPS for the quarter, topping the consensus estimate of $3.77 by $0.04. The business had revenue of $5.44 billion during the quarter, compared to the consensus estimate of $5.38 billion. Becton, Dickinson and Company had a net margin of 8.55% and a return on equity of 14.89%. Becton, Dickinson and Company’s revenue was up 6.9% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $3.42 EPS. Research analysts forecast that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, December 31st. Stockholders of record on Monday, December 9th were paid a dividend of $1.04 per share. The ex-dividend date was Monday, December 9th. This represents a $4.16 dividend on an annualized basis and a dividend yield of 1.78%. This is a positive change from Becton, Dickinson and Company’s previous quarterly dividend of $0.95. Becton, Dickinson and Company’s dividend payout ratio (DPR) is 70.03%.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.